Asset profile

HJB647

Small molecule

Phase 1Undisclosed / early pipeline
Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Heart Failure · Phase 1

How the evidence outlook works ↗

Competitive landscape

113 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 113 same-indication; 106 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HJB647: this drugPhase 1Small molecule—
Aprocitentan (Tryvio)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)
Baxdrostat (Baxfendy)ApprovedSmall moleculeAldosterone synthase (CYP11B2)
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2
Epoprostenol (Flolan)ApprovedSmall moleculeIP receptor (prostacyclin pathway)
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletion
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletion
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptor
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2
Icodextrin (peritoneal Ultrafiltration) (Extraneal)ApprovedDevice Solution (peritoneal Dialysis)Peritoneal ultrafiltration
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)
Ivabradine (Corlanor)ApprovedSmall moleculeIf (funny) channel
Mavacamten (Camzyos)ApprovedSmall moleculeCardiac myosin (inhibitor)

…and 98 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
December 2026 (2)
Phase 1Heart FailureRecruiting
Est. primary completion 2026-12-08 · NCT07465653 · CT.gov ↗
What to watch
Unlock with Research ↗
Phase 1HypertensionRecruiting
Est. primary completion 2026-12-25 · NCT07644364 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 1 (2)